Clinical activity and safety of combination immunotherapy with interferon-α2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma

Haematologica

Volumn 86, Issue 9, 2001, Pages 951-958

  Sacchi, S ^a   Federico, M ^a   Vitolo, U ^a   Boccomini, C ^a   Vallisa, D ^a   Baloini, L ^a   Petrini, M ^a   Rupoli, S ^a   Di Raimondo, F ^a   Merli, F ^a   Liso, V ^a   Tabilio, A ^a   Saglio, G ^a   Vinci, G ^a   Brugiatelli, M ^a   Dastoli, G ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Clinical trials; Hematologic malignancies

Indexed keywords

ALPHA2A INTERFERON; PROTEIN BCL 2; RITUXIMAB;

ADULT; ARTICLE; BONE MARROW; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RECURRENT CANCER; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INTERFERON ALFA-2A; ITALY; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; RECURRENCE; SAFETY; TREATMENT OUTCOME;

EID: 0034791843     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Coherent view of non-Hodgkin's lymphoma
2. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project
3. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
4. Alkylating agent therapy for follicular lymphoma
5. Conventional treatment of indolent lymphomas: Role of CHOP or CHOP-like chemotherapy
6. Purine analogs in the management of indolent lymphoproliferative disorders
7. Long term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft
8. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
9. Characterization of a human B lymphocyte-specific antigen
10. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
11. CD20 workshop panel report
12. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
13. Chimeric anti-CD20 antibody (IDEC-C2B8) is a poptotic and sensitizes drug resistant human B-cell lymphomas and AIDS-related lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins
14. The anti-tumor effect of monoclonal anti-CD20 antibody (mAB) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines
15. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
16. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
17. IDEC-C2B8 rituximab anti CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
18. K. Rituximab chimeric anti CD-20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four dose treatment program
19. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
20. Extended rituximab (anti CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
21. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients
22. Effect of in vitro exposure to interferon α (IFNα) on CD20 expression in chronic lymphocytic leukemia cells (CLL)
23. Enhanced NK cell activity in mice injected with interferon and interferon inducers
24. Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity
25. Effect of α-interferon on immune function
26. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
27. Non-parametric estimation from incomplete observations
28. Interferon acts on human B lymphocytes to modulate immunoglobulin synthesis
29. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes
30. Interferon: An inducer of macrophage activation by polyanions
31. Interferon activated genes
32. A molecular basis for MHC class II-associated autoimmunity
33. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo
34. Recombinant α-IFN enhances tumor targeting of an antimelanoma monoclonal antibody in vivo
35. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a
36. Interferon α plus chemotherapy for non-Hodgkin's lymphoma: Five-year follow-up
37. Doxorubicin-containing regimen with or without interferon α-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial
38. Maintenance of remission with human recombinant interferon α-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma
39. Current status and perspectives of therapy for follicular lymphomas
40. Treatment of non-follicular indolent lymphoma